Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | SHBG | P04278 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.64 |
| ▸ | GUSB | P08236 | 1/20 | 0.64 |
| ▸ | G6PD | P11413 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.53 |
| ▸ | GPR183 | P32249 | 6/20 | 0.51 |
| ▸ | RORA | P35398 | 2/20 | 0.51 |
| ▸ | RORC | P51449 | 2/20 | 0.51 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.51 |
| ▸ | OSBP | P22059 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601163 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL14492219 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL14581228 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL14613791 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL10301214 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL1952526 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL301939 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL14613826 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL2921296 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL13753025 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324835-A | Method for preparing 7 beta-hydroxy dehydroepiandrosterone by utilizing dehydroepiandrosterone and application | 上海格苓凯生物科技有限公司 | 2024-07-12 | — | — | CN | claimed |
| EP-2300489-B1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS | HARBOR THERAPEUTICS INC (US) | 2015-11-11 | — | — | EP | claimed |
| US-20130066087-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS-2 | Harbor Therapeutics, Inc. (US) | 2013-03-14 | — | — | US | claimed |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| US-8309746-B2 | Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds | Harbor Therapeutics, Inc (US) | 2012-11-13 | — | — | US | claimed |
| EP-2300489-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS | Harbor BioSciences, Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| WO-2008065408-A9 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2011-03-03 | — | — | WO | claimed |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER-FLEMING LIMITED (GB) | 2010-06-03 | — | — | US | claimed |
| US-20090326251-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | claimed |
| WO-2009149392-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | WO | claimed |
| US-20070066579-A1 | 5-androsten-3beta-ol steroid intermediates and processs for their preparation | WHITE MICHAEL J | 2007-03-22 | — | — | US | claimed |
| EP-1679317-A2 | 5-Androsten-3 -ol steroid intermediates and processes for fheir preparation | Pharmacia & Upjohn Company LLC (US) | 2006-07-12 | — | — | EP | claimed |
| US-20050256095-A1 | Asthma and colitis treatment methods | BIOVIE INC. | 2005-11-17 | — | — | US | claimed |
| EP-1294381-B1 | NEUROPROTECTIVE 7-BETA-HYDROXYSTEROIDS | HUNTER FLEMING LTD (GB) | 2005-08-31 | — | — | EP | claimed |
| EP-1534732-A2 | 5 ANDROSTEN-3&bgr;-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION | Pharmacia & Upjohn Company LLC (US) | 2005-06-01 | — | — | EP | claimed |
| US-20050075321-A1 | Neurological disorder treatment methods | BIOVIE INC. | 2005-04-07 | — | — | US | claimed |
| EP-1422234-A2 | Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-05-26 | — | — | EP | claimed |
| WO-2004016640-A2 | 5 ANDROSTEN-3β-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-02-26 | — | — | WO | claimed |
| US-20040034215-A1 | 5-Androsten-3beta-ol steroid intermediates and processes for their preparation | PHARMACIA & UPJOHN COMPANY | 2004-02-19 | — | — | US | claimed |
| US-20030060425-A1 | Immune modulation method using steroid compounds | BIOVIE INC. | 2003-03-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060425-A1 | Immune modulation method using steroid compounds | HSD3B1, NR5A1, HSD17B1 | CA1 4009/4885CA2 4243/4885CA9 4274/4885 |
| US-20070066579-A1 | 5-androsten-3beta-ol steroid intermediates and processs for their preparation | CYP17A1, NR5A1, HSD3B2 | CA1 3410/4885CA2 4638/4885CA9 3859/4885 |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | PTGES2, PTGES, PTGS2 | CA1 4532/4885CA2 3492/4885CA9 4507/4885 |
| US-20090326251-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS | HSD17B11, ESRRA, HSD17B7 | CA1 3733/4885CA2 4057/4885CA9 1787/4885 |
| US-20130066087-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS-2 | HSD17B11, ESRRA, ESRRB | CA1 3861/4885CA2 3327/4885CA9 2044/4885 |
| US-20050075321-A1 | Neurological disorder treatment methods | HSD17B1, HSD17B3, HSD3B1 | CA1 1832/4885CA2 3530/4885CA9 4573/4885 |
| US-20040034215-A1 | 5-Androsten-3beta-ol steroid intermediates and processes for their preparation | CYP17A1, NR5A1, HSD3B2 | CA1 3112/4885CA2 4632/4885CA9 3746/4885 |
| US-20100137270-A1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | PTGES2, PTGES, PTGS2 | CA1 4532/4885CA2 3492/4885CA9 4507/4885 |
| US-20050256095-A1 | Asthma and colitis treatment methods | HSD3B1, HSD17B1, HSD11B1 | CA1 2438/4885CA2 2263/4885CA9 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.